MyoTreat Myopia - from genes and environment to cellular responses and treatment
- Coordinator
- Eberhard Karls Universitaet Tuebingen, Germany
- Runs
- 1 December 2023 to 31 May 2028
- Status
- Running
- EU funding
- €2.7m
- Total cost
- —
- Partners
- 12 organisations in 7 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101119501
What the project is doing
In the project's own words, from its summary on CORDIS.
In modern industrial societies, myopia has become an important ocular health problem of young people, due to its increased incidence and associated complications, which pose a significant risk of blindness already in the middle life span. Current treatment options have limited effects with a maximum reduction of axial elongation by about 0.4 mm over several years, equivalent to a reduction in myopia by only about 1 D.
Eye growth is controlled by an interplay of different biochemical pathways, one inhibitory (stimulated by image plane in front of the retina) and one stimulatory (image plane behind the retina). A novel future strategy would be to activate the inhibitory pathways rather than inhibit the growth stimulating pathways (standard target in most studies). At present, interventions to activate growth inhibition are poorly studied.
The influence of environmental factors (spectral composition of ambient light) and gene-environment interactions (specific gene variants and their interaction with key lifestyle exposures) on eye growth and refractive development will be investigated. New pharmacological targets will be identified and tested, and biomarkers established to detect the onset of myopia at an earlier stage. It will be studied how choroidal hypoxia relates to choroidal thinning and axial eye growth and how it interacts with the metabolic processes in the retina and sclera.
New measurement techniques will be developed that implement artificial intelligence algorithms to improve diagnostics in myopia studies, especially in the periphery of the visual field. The proposed intersectorial and interdisciplinary ""MyoTreat"" project (including anatomy, physiology, pharmacology, optics, and genetics) will train PhD students in myopia research and generate and disseminate novel research results. The ultimate scientific goal is to identify new strategies for myopia therapy through hypothesis-driven translational research in various animal models as well as in humans.""
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Eberhard Karls Universitaet Tuebingen | Tuebingen | Germany | Coordinator |
| Paracelsus Medizinische Privatuniversitat Salzburg - Privatstiftung | Salzburg | Austria | Participant |
| Institut Fur Molekulare Und Klinische Ophthalmologie Basel | Basel | Switzerland | Associatedpartner |
| TRB Chemedica International SA | Geneve | Switzerland | Associatedpartner |
| Carl Zeiss Vision International GmbH | Aalen | Germany | Participant |
| Integragen SA | Evry | France | Associatedpartner |
| Sorbonne Universite | Paris | France | Participant |
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Participant |
| Signify Netherlands BV | Eindhoven | Netherlands | Associatedpartner |
| Folkehelseinstituttet | Oslo | Norway | Associatedpartner |
| Universitetet I Sorost-Norge | Horten | Norway | Participant |
| Cardiff University | Cardiff | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI